{"id":501079,"date":"2020-08-07T19:46:02","date_gmt":"2020-08-07T19:46:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=501079"},"modified":"2020-08-07T19:46:02","modified_gmt":"2020-08-07T19:46:02","slug":"chronic-inducible-urticaria-market-size-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-inducible-urticaria-market-size-share-trends-epidemiology-forecast-till-2030_501079.html","title":{"rendered":"Chronic Inducible Urticaria Market, Size, Share, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Inducible Urticaria Market, Size, Share, Trends, Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Chronic Inducible Urticaria Market, Size, Share, Trends, Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Chronic Inducible Urticaria Market Insights, Epidemiology, and Market Forecast 2030\u2019 report, delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Chronic Inducible Urticaria (CIndU) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. <\/div>\n<p style=\"text-align: justify;\">Chronic Inducible Urticaria is a group of chronic urticarias characterized by the appearance of recurrent wheals, recurrent angioedema, or both, as a response to specific triggers.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-inducible-urticaria-market-forecast\">market size of Chronic Inducible Urticaria<\/a><\/strong> is anticipated to rise at a significant CAGR during the study period of 2017&ndash;2030. Among all 7MM, the United States accounted for the largest Chronic Inducible Urticaria market size.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/4900ddfa849186e88e996408d030ceab.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Among EU5 countries, Germany had the largest <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-inducible-urticaria-market-forecast\">market size of Chronic Inducible Urticaria<\/a><\/strong>, with&nbsp;<strong>USD 172 million<\/strong>&nbsp;in 2017, while Spain had the smallest Chronic Inducible Urticaria market size with&nbsp;<strong>USD 104.5 million<\/strong>&nbsp;in 2017.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Inducible Urticaria market drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Need for curative therapy<\/li>\n<li>Increasing awareness<\/li>\n<li>Rising prevalence<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Inducible Urticaria market barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Need for biomarkers<\/li>\n<li>Complex pathophysiology<\/li>\n<li>Patient adherence<\/li>\n<li>Need for Chronic Inducible Urticaria specific population studies&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The therapeutic goal of Chronic Inducible Urticaria management primarily focuses on achieving complete symptom control by trigger avoidance and desensitization, blocking the effects of mast cell mediators (non- sedating, second-generation antihistamines), and prevention of mast cell degranulation. Currently, there is no approved therapy for Chronic Inducible Urticaria treatment apart from symptomatic management. The pipeline scenario does not show a particularly close picture with only one major player making significant inroads in the largely untapped market. <strong>AK002 (Antolimab), being developed by Allakos Pharma<\/strong>, is the only drug with the potential to enter the arena during the forecast period and has completed Phase II trials.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-inducible-urticaria-market-forecast\" target=\"_blank\">Request for sample pages<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-inducible-urticaria-market-forecast\" target=\"_blank\">Table of contents<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><span>1 Key Insights<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2 Executive Summary of Chronic Inducible Urticaria<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3 SWOT Analysis for Chronic Inducible Urticaria<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4 Chronic Inducible Urticaria Epidemiology Overview at a Glance<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1 Patient Share (%) Distribution of Chronic Inducible Urticaria in 2017<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.2 Patient Share (%) Distribution of Chronic Inducible Urticaria in 2030<\/p>\n<p style=\"text-align: justify;\"><span>5 Chronic Inducible Urticaria Market Overview at a Glance<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1 Market Share (%) Distribution of Chronic Inducible Urticaria in 2017<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.2 Market Share (%) Distribution of Chronic Inducible Urticaria in 2030<\/p>\n<p style=\"text-align: justify;\"><span>6 Disease Background and Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.1 Introduction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.2 Types<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.3 Pathophysiology<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.4 Clinical features<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.5 Diagnosis<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.6 Clinical manifestation<\/p>\n<p style=\"text-align: justify;\"><span>7 Epidemiology and Patient Population<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.1 Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.2 Total Prevalent Population of CIndU in 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.3 Assumptions and Rationale: 7MM<\/p>\n<p style=\"text-align: justify;\"><span>8 Country Wise-Epidemiology of Chronic Inducible Urticaria<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.1 The United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.1.1 Diagnosed Prevalent cases of CU in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.1.2 Diagnosed Prevalent cases of CIndU in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.1.3 Prevalence of Chronic Inducible Urticaria by Types in the United States<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.2 EU5<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.1 Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.2 France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.3 Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.4 Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.2.5 The United Kingdom<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.3 Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.3.1 Diagnosed Prevalent cases of CU in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.3.2 Diagnosed Prevalent cases of CIndU in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.3.3 Prevalence of Chronic Inducible Urticaria by Types in Japan<\/p>\n<p style=\"text-align: justify;\"><span>9 Treatment and Management<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">9.1 Guidelines<\/p>\n<p style=\"text-align: justify;\"><span>10 Case Study<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.1 Severe cold urticaria including anaphylaxis<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.2 Severe symptomatic dermographism (urticaria factitia)<\/p>\n<p style=\"text-align: justify;\"><span>11 Patient Journey<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12 Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>13 Emerging Therapies<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1 AK002: Allakos Inc.<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">13.1.1 Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">13.1.2 Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">13.1.3 Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\"><span>14 Other Promising Therapies<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.1 CDX-0159: Celldex Therapeutics<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.1.1 Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.1.2 Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.1.3 Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\"><span>15 Chronic Inducible Urticaria: Seven Major Market Analysis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.1 Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.2 Market Size of Chronic Inducible Urticaria (CIndU) in 7MM<\/p>\n<p style=\"text-align: justify;\"><span>16 Market Outlook by Country<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.1 Assumption and Rationale<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.2 United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.2.1 Total Market size of Chronic Inducible Urticaria (CIndU)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.2.2 Chronic Inducible Urticaria Market Size by Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.3 Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.3.1 Total Market size of Chronic Inducible Urticaria (CIndU)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.3.2 Chronic Inducible Urticaria Market Size by Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.4 France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.4.1 Total Market size of Chronic Inducible Urticaria (CIndU)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.4.2 Chronic Inducible Urticaria Market Size by Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.5 Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.5.1 Total Market size of Chronic Inducible Urticaria (CIndU)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.5.2 Chronic Inducible Urticaria Market Size by Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.6 Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.6.1 Total Market size of Chronic Inducible Urticaria (CIndU)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.6.2 Chronic Inducible Urticaria Market Size by Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.7 UK<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.7.1 Total Market size of Chronic Inducible Urticaria (CIndU)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.7.2 Chronic Inducible Urticaria Market Size by Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.8 Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.8.1 Total Market size of Chronic Inducible Urticaria (CIndU)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.8.2 Chronic Inducible Urticaria Market Size by Therapies<\/p>\n<p style=\"text-align: justify;\"><span>17 Market Drivers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>18 Market Barriers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>19 Appendix<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19.1 Report Methodology<\/p>\n<p style=\"text-align: justify;\"><span>20 DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\"><span>21 Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span>22 About DelveInsight<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-inducible-urticaria-market-size-share-trends-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-inducible-urticaria-market-size-share-trends-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Chronic Inducible Urticaria Market Insights, Epidemiology, and Market Forecast 2030\u2019 report, delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Chronic Inducible Urticaria (CIndU) in the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-inducible-urticaria-market-size-share-trends-epidemiology-forecast-till-2030_501079.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-501079","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=501079"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501079\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=501079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=501079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=501079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}